| A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction M Valgimigli, N Mittmann, DJ Cohen, G Campo, PK Isogai, SJ Seung, ... International journal of cardiology 128 (1), 53-61, 2008 | 1 | 2008 |
| Addendum to CADTH’s guidelines for the economic evaluation of health technologies: specific guidance for oncology products N Mittmann, WK Evans, A Rocchi, CJ Longo, HJ Au, D Husereau, ... Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009 | 26 | 2009 |
| Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of … N Mittmann, HJ Au, D Tu, CJ O’Callaghan, PK Isogai, CS Karapetis, ... J Natl Cancer Inst 101 (17), 1182-1192, 2009 | 17 | 2009 |
| Basic Research in Cancer Population-based home care services in breast cancer: utilization and costs N Mittmann, PK Isogai, R Saskin, N Liu, JM Porter, MC Cheung, NB Leighl, ... | | |
| Comprehensiveness of quality of life instruments in capturing concerns related to chemotherapy-induced neutropenia LA Nina, P Isogai, N Mittmann, C DeAngelis, M Cheung, K Sandra, ... Blood, The Journal of the American Society of Hematology 112 (11), 1311-1311, 2008 | 2 | 2008 |
| Comprehensiveness of Quality of Life Instruments in Capturing Concerns Related to Chemotherapy-Induced Neutropenia N Lathia, P Isogai, N Mittmann, C DeAngelis, M Cheung, K Sandra, ... BLOOD 112 (11), 474-474, 2008 | 1 | 2008 |
| Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients N Lathia, PK Isogai, CD Angelis, TJ Smith, M Cheung, N Mittmann, ... Journal of the National Cancer Institute 105 (15), 1078-1085, 2013 | 47 | 2013 |
| Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis against Febrile Neutropenia in Lymphoma Patients Receiving R-CHOP Chemotherapy. N Lathia, PK Isogai, S Walker, MC Cheung, M Krahn, C DeAngelis, ... Blood, The Journal of the American Society of Hematology 114 (22), 2475-2475, 2009 | 3 | 2009 |
| Derivation of utility values from EORTC QLQ-C30 values in lung cancer R Jang, PK Isogai, N Mittmann, PA Bradbury, F Shepherd, R Feld, ... JOURNAL OF THORACIC ONCOLOGY 4 (9), S420-S421, 2009 | 1 | 2009 |
| Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer RW Jang, PK Isogai, N Mittmann, PA Bradbury, FA Shepherd, R Feld, ... Journal of Thoracic Oncology 5 (12), 1953-1957, 2010 | 59 | 2010 |
| Deriving Health Utility Values From a Health-Related Quality of Life Instrument in Non-Hodgkin Lymphoma Patients N Lathia, PK Isogai, JS Hoch, C De Angelis, M Cheung, S Walker, ... Blood, The Journal of the American Society of Hematology 118 (21), 2065-2065, 2011 | | 2011 |
| Economic analysis of alemtuzumab in fludarabine-refractory and relapsed chronic lymphocytic leukemia in Canada PK Isogai, M Cheung, N Mittmann Blood, The Journal of the American Society of Hematology 112 (11), 2375-2375, 2008 | | 2008 |
| Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non–small cell lung cancer PA Bradbury, D Tu, L Seymour, PK Isogai, L Zhu, R Ng, N Mittmann, ... Journal of the National Cancer Institute 102 (5), 298-306, 2010 | 86 | 2010 |
| Economic evaluation of aclasta (R)(zoledronic acid 5 mg) versus actonel (R)(risedronate) in treatment of Paget's disease N Mittmann, PK Isogai, JD Adachi, CM Kindundu, M Barbeau OSTEOPOROSIS INTERNATIONAL 17, S189-S189, 2006 | | 2006 |
| Economic evaluation of Aclasta (TM)(zoledronic acid 5 mg) versus Actonel (TM)(risedronate) in treatment of Paget's disease N Mittmann, PK Isogai, JD Adachi, CM Kindundu, M Barbeau OSTEOPOROSIS INTERNATIONAL 17, S38-S39, 2006 | | 2006 |
| Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document N Mittmann, WK Evans, A Rocchi, CJ Longo, HJ Au, D Husereau, ... Journal of Clinical Oncology 27 (15_suppl), e17572-e17572, 2009 | | 2009 |
| Eliciting patients’ preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment N Lathia, PK Isogai, SE Walker, C De Angelis, MC Cheung, JS Hoch, ... Supportive Care in Cancer 21 (1), 245-251, 2013 | 15 | 2013 |
| End-of-life home care utilization and costs in patients with advanced colorectal cancer N Mittmann, N Liu, JM Porter, PK Isogai, R Saskin, MC Cheung, NB Leighl, ... J Community Support Oncol 12 (3), 92-98, 2014 | 12 | 2014 |
| Evaluation of the cost-effectiveness of electrical stimulation therapy for pressure ulcers in spinal cord injury N Mittmann, BC Chan, BC Craven, PK Isogai, P Houghton Archives of physical medicine and rehabilitation 92 (6), 866-872, 2011 | 31 | 2011 |
| Factors influencing patient preferences for outpatient treatment of febrile neutropenia. N Lathia, PK Isogai, C De Angelis, S Walker, MC Cheung, N Mittmann Journal of Clinical Oncology 29 (15_suppl), 6041-6041, 2011 | 1 | 2011 |
